🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06857084
Recruiting Observational

Evaluation Of Outcomes Following Rotator Cuff Repair Using the REGENETEN Bioinductive Implant

NCT06857084 · tracked via the Priya Life Science UK tracker
Sponsor
Smith & Nephew, Inc.
Phase
Observational
Started
2020-10-01
Last updated
2026-06-01

Condition(s) studied

Rotator Cuff Injuries

Investigational drug(s) / intervention(s)

Arthroscopic rotator cuff repair with REGENETEN Bioinductive Implant augmentation

Arthroscopic rotator cuff repair with REGENETEN Bioinductive Implant augmentation: Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue.

Study summary

This prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients who are undergoing rotator cuff repair using the REGENETEN◊ Bioinductive Implant System. The Registry will include up to 50 centers in the United Kingdom (UK), Europe, Australia, and up to 400 patients for the initial evaluation.

Patients will be treated and evaluated according to standard medical care. Outcome data is collected up to 2 years post-surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Subject requires Arthroscopic rotator cuff repair (ARCR); * Patients aged over 18 years old at the time of consent and providing baseline data before undergoing rotator cuff repair surgery (either partial or full thickness tears) will be eligible for this prospective registry. Exclusion Criteria: * Subject who, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the registry including mental illness, intellectual disability, and drug or alcohol abuse. * Subjects who do not meet the indication or are contraindicated according to specific Smith+Nephew REGENETEN System's Instructions for Use (IFUs); * Subject that meets the definition of a Vulnerable Subject per ISO14155:2020 Section 3.44.

Primary outcome measure(s)

Trial sites (22)

FacilityCityRegionStatus
Melbourne Orthopaedic Group Windsor Victoria Recruiting
Schoen Klinik Lorsch Lorsch Rhine Recruiting
Schoen Klinik Dusseldorf Düsseldorf Germany Recruiting
Malteser Waldkrankenhaus Erlangen Erlangen Germany Recruiting
Sporthopaedie Heidelberg Heidelberg Germany Recruiting
St. Anna Hospital Herne Germany Recruiting
Artemed Klinikum München Süd München Germany Recruiting
OrthoMedicum Mittelhessen Stadtallendorf Germany Recruiting
Regional General Hospital F. Miulli Acquaviva delle Fonti Apulia Recruiting
Ospedale Israelitico Roma Italy Recruiting
Ospedale di Sassuolo Sassuolo Italy Recruiting
Manchester University NHS Foundation Trust Manchester Greater Manchester Recruiting
Spire Harpenden Hospital Harpenden Hertordshire Recruiting
Spire Montefiore Brighton Hove Recruiting
Burnley General Hospital Burnley Lancashire Recruiting
Burnley General Teaching Hospital Burnley Lancashire Recruiting
Manchester University NHS Foundation Trust Manchester Lancashire Recruiting
Grantham and District Hospital Grantham Lincolnshire Recruiting
University College London Hospitals London London Recruiting
Cleveland Clinic London Hospital London London Recruiting
Sulis Hospital Bath Bath Somerset Recruiting
West Hertfordshire Hospitals NHS Trust Hertford United Kingdom Not Yet Recruiting

More Smith & Nephew, Inc. trials in the UK

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06857084 on ClinicalTrials.gov ↗ ← All trials in the UK